Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis
Introduction
Squamous cell carcinoma is the most common cancer that occurs in the oral cavity, with an estimated 300,000 new cases worldwide each year [1], [2], [3]. Locoregionally advanced oral cavity cancers are aggressive tumours with elevated probabilities of relapse after definitive treatment with surgery or radiotherapy (RT). Therefore, a multimodal approach combining surgery and postoperative radiotherapy or chemoradiotherapy has been proposed [4].
There are insufficient reports from phase III prospective randomised clinical studies to show an ideal approach for patients with locally advanced oral cavity malignancies. Guidelines and treatment options are based upon studies that included a majority of patients with primary cancers at other head and neck sites and also retrospective data.
In general, the primary therapy for locally advanced oral cavity squamous cell carcinoma (SCC) usually involves surgery followed by radiotherapy and chemotherapy (in the setting of high-risk pathological features such as positive resection margins, and extracapsular nodal spread). Upfront chemoradiation is an option for patients who decline surgery, have unresectable tumour and/or are medically inoperable [5]. Nevertheless, overall survival and tumour control are disappointing, because approximately 50% of the patients will die after 5 years from diagnosis, due to local and/or systemic recurrences [6]. Although improvement in surgical techniques and use of adjuvant treatments have been observed, the 5-year survival rate has not improved considerably in recent years, persisting at 55% [7], [8].
New treatment strategies for locally advanced oral cavity SCC have been tested, including preoperative chemotherapy. Induction chemotherapy might reduce tumour burden, ameliorate tumour-related symptoms and improve surgical results. Moreover, induction chemotherapy could treat micrometastatic disease early on, potentially leading to improved overall clinical outcomes [9].
This study was performed to assess the effectiveness and safety of induction chemotherapy prior to surgery for untreated oral cavity SCC patients.
Section snippets
Study design
This was a systematic review carried out in accordance with The Cochrane Collaboration Handbook of Interventions Systematic Reviews [10]. The manuscript was arranged using the PRISMA Statement as reporting guidance [11].
Criteria for considering studies for this review
We included trials that assessed any induction chemotherapy strategy followed by surgery with or without postoperative radiotherapy compared with surgery with or without postoperative radiotherapy. Only randomised controlled trials were considered. Cluster or crossover designs
Study selection and characteristics of the included studies
The flowchart of the retrieved studies and the characteristics of included studies are presented in Fig. 1 and Table 1, respectively. Three papers, reporting two studies fulfilled the eligibility criteria (Bossi et al. [12], Licitra et al. [13], Zhong et al. [14]).
451 patients were randomly assigned to induction chemotherapy followed by surgery with or without radiotherapy (n = 226), versus surgery with or without radiotherapy (n = 225). Most of the patients were male (75.8%); tumours at clinical
Discussion
Standard management for advanced oral cavity SCC comprises a multidisciplinary approach including surgery and postoperative radiotherapy associated or not with chemotherapy. Despite technical improvements in the involved therapeutic modalities [15], [16], [17], long-term overall survival and tumour control are still unsatisfactory [8], [9].
The use of chemotherapy in advanced head and neck SCC has shown a significant advantage in terms of overall survival, when delivered concurrently with
Conflict of interest statement
None.
References (24)
Oral cancer
Mayo Clin Proc
(2007)- et al.
Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial
Ann Oncol
(2014) - et al.
Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis
Radiother Oncol
(2014) - et al.
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
Radiother Oncol
(2009) - et al.
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
Ann Oncol
(2014) - et al.
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
Lancet Oncol
(2013) The World Oral Health Report 2003: continuous improvement of oral health in the 21st century–the approach of the WHO Global Oral Health Programme
Community Dent Oral Epidemiol
(2003)- et al.
Global cancer statistics, 2012
CA Cancer J Clin
(2015) - et al.
Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Cochrane Database Syst Rev
(2011) - et al.
Contemporary management of cancer of the oral cavity
Eur Arch Otorhinolaryngol
(2010)
Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis
Oncologist
Oral cancer and precancerous lesions
CA Cancer J Clin
Cited by (57)
The efficacy of neoadjuvant chemotherapy as compared to upfront surgery for the management of oral squamous cell carcinoma: a systematic review and meta-analysis
2024, International Journal of Oral and Maxillofacial SurgeryRevisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy
2023, Cancer Treatment ReviewsThe Potential Impact and Usability of the Eighth Edition TNM Staging Classification in Oral Cavity Cancer
2021, Clinical OncologyCitation Excerpt :There may be a role for exploring radiation dose intensification for progressive disease postoperatively [28] and areas prone to in-field recurrence. In terms of systemic treatment intensification, there is generally a lack of evidence supporting the use of induction chemotherapy [29], but a subgroup analysis from a systematic review [30] showed that induction chemotherapy may improve survival in patients with clinical N2+ disease. The relatively modest chemotherapy rate (47%) in our pN+_ENE+ cohort suggests that intensification of chemotherapy could be challenging.
Locally Advanced oral Squamous cell Carcinomas: Auditing and Outcome Appraisal
2024, Indian Journal of Otolaryngology and Head and Neck Surgery